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A B S T R A C T
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:
Primary objectives
To determine the diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra for a) PTB in children presumed to have tuberculosis; b)
lymph node tuberculosis in children presumed to have tuberculosis; c) tuberculousmeningitis in children presumed to have tuberculosis;
and d) rifampicin resistance in children presumed to have tuberculosis.
For tuberculosis detection, the role of the index tests would be a replacement for standard practice.
For rifampicin resistance detection, the role of the index tests would be an initial replacement test for culture-based drug susceptibility
testing.
B A C K G R O U N D
Tuberculosis is one of the top 10 causes of death and the leading
cause from a single infectious agent (above HIV/AIDS), causing
an estimated 1.6million deaths in 2017.Globally during that year,
an estimated 10 million people developed tuberculosis disease, in-
cluding one million children (WHO 2018a). Recent models that
have been accepted and supported by the World Health Organi-
zation (WHO) suggest that there is substantial underreporting as
well as underdiagnosis of child tuberculosis. Even accounting for
underdiagnosis, children represent 10%of the annual 10.4million
incident cases. Furthermore, tuberculosis-associated deaths take a
disproportionate toll in children: 253,000 deaths were estimated
in 2016 in children below 15 years, accounting for 6.9% of the
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total deaths notified in that year; of these deaths, 80% occurred
in children under five years of age (Dodd 2017; Jenkins 2017).
Estimates suggest that themajority of deaths occurring in children
occur in undiagnosed cases and represent a missed opportunity to
start adequate treatment (Jenkins 2017). Tuberculosis treatment
in children follows the same principles as that in adults, with the
same drugs used in most cases. The standard four-drug combina-
tion regimen of isoniazid, rifampicin, pyrazinamide, and etham-
butol given daily for a period of two months followed by isoni-
azid and rifampicin given daily for additional four to six months
is used for the treatment of drug-susceptible tuberculosis, both
the pulmonary and extrapulmonary forms with the exception of
central nervous system tuberculosis where the treatment with iso-
niazid and rifampicin is extended to a total of 12 months. The
recent introduction of paediatric fixed-dose combinations with
optimized dosing and taste masking has improved the efficiency
of treatment. Treatment of drug-resistant tuberculosis in children
generally has better outcomes than in adults, and in August 2018,
the WHO released a rapid communication containing new rec-
ommendations for treatment, including the use of all-oral regi-
mens (WHO 2018b; Furin 2019).
The diagnosis of child tuberculosis relies on a mix of clinical, epi-
demiological, radiological, and laboratory information. Child tu-
berculosis disease is typically paucibacillary (tuberculosis disease
caused by a smaller number of bacteria), and young children can-
not voluntarily produce sputum specimens (Marais 2005; Theart
2005). Hence, even under ideal clinical and laboratory conditions,
only 30% to 40% of child tuberculosis cases are microbiologi-
cally confirmed (Dunn 2016). The probability of a microbiolog-
ical confirmation is increased in children with more severe or ad-
vanced disease (Marais 2006c; Marais 2006d). However, the di-
agnostic gap also exists because conventional smear microscopy,
which is of little value in diagnosing child tuberculosis, remains the
most used and widely available tuberculosis diagnostic method in
low- and middle-income countries. Tuberculosis culture methods
have shown a greater, yet highly variable, sensitivity in child tuber-
culosis (Frigati 2015; Chiang 2017); unfortunately, tuberculosis
culture is not widely available in high-burden settings to support
diagnosis.
Xpert MTB/RIF represents a promising diagnostic modality for
child tuberculosis. Since 2010 the WHO has recommended the
use of Xpert MTB/RIF as the preferred initial microbiological
test for people thought to have multidrug-resistant tuberculosis
or HIV-associated tuberculosis (strong recommendation), and has
included children with presumed tuberculosis on the strength of
evidence reported in adults (WHO 2011). In 2013 this guidance
was updated with a recommendation specific to children, that is
that Xpert MTB/RIF should be used as the preferred initial di-
agnostic test in children thought to have multidrug-resistant tu-
berculosis or HIV-associated tuberculosis (strong recommenda-
tion, very low-quality) and as the initial diagnostic test in all chil-
dren with presumptive tuberculosis (conditional recommendation
acknowledging resource implications, very low-quality evidence)
(WHO 2013). At present, the WHO supports the use of Xpert
MTB/RIF for diagnosis of child tuberculosis in four scenarios:
• the initial diagnostic test of choice, rather than
conventional smear microscopy or culture (conditional
recommendation acknowledging resource implications, very low-
quality evidence (also called certainty of the evidence);
• diagnosis in children suspected of having drug-resistant
tuberculosis or HIV-associated tuberculosis (strong
recommendation, very low-quality evidence);
• as a replacement test for specific non-respiratory specimens
(lymph nodes and other tissues) in children presumed to have
extrapulmonary tuberculosis (conditional recommendation, very
low-quality evidence); and
• as the preferred initial diagnostic on cerebrospinal fluid
(CSF) in children suspected of having tuberculous meningitis
(strong recommendation given the urgency of rapid diagnosis,
very low-quality evidence) (WHO 2014a).
The WHO does not currently recommend Xpert MTB/RIF for
use on other specimen types, and the existing guidelines acknowl-
edge that all current recommendations regarding use of Xpert
MTB/RIF in children rely on “very low-certainty evidence” and
are currently evolvingwith the expansionof the use ofXpertMTB/
RIF Ultra (Xpert Ultra) (WHO 2017).
A non-inferiority analysis of XpertUltra compared toXpertMTB/
RIF found thatXpertUltra has higher sensitivity thanXpertMTB/
RIF, particularly in smear-negative, culture-positive specimens and
in specimens from HIV-positive patients. Xpert Ultra was also
found to have accuracy that was at least as good as Xpert MTB/
RIF for rifampicin resistance detection. However, it was noted
that Xpert Ultra may have reduced specificity in high tuberculosis
burden settings. The current WHO recommendations for the use
of Xpert MTB/RIF now also apply to the use of Xpert Ultra as
the initial diagnostic test for all adults and children with signs and
symptoms of tuberculosis and in the testing of selected extrapul-
monary specimens (cerebrospinal fluid, lymph nodes and tissue
specimens). However, a negative test result does not exclude tu-
berculosis in children (WHO 2017). This systematic review will
estimate and compare the diagnostic accuracy of Xpert MTB/RIF
and Xpert Ultra in children presumed to have pulmonary tuber-
culosis (PTB) or specific forms of extrapulmonary tuberculosis.
Target condition being diagnosed
Tuberculosis is an infectious disease caused by bacteria within
the Mycobacterium tuberculosis complex, most commonly My-
cobacterium tuberculosis (M tuberculosis). Typically disseminated
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through the air, M tuberculosis predominantly affects the lungs,
causing PTB, and less typically can cause disease in other organs of
the body in extrapulmonary tuberculosis forms. Lymph node tu-
berculosis is the most common extrapulmonary tuberculosis pre-
sentation in children, while tuberculous meningitis results in the
highest morbidity and mortality. In this review we will limit extra-
pulmonary tuberculosis to lymph node tuberculosis and tubercu-
lous meningitis because other forms of extrapulmonary tubercu-
losis in children are less common, and literature supporting Xpert
(Xpert MTB/RIF and Xpert Ultra) as a diagnostic tool in other
forms of child extrapulmonary tuberculosis is sparse.
The natural history of tuberculosis in children is distinct from
adults due to the more frequent progression to primary tubercu-
losis disease (Marais 2004). Children under five years of age are at
particularly high risk of progression to tuberculosis disease follow-
ing infection, but the risk for older children and adolescents is also
higher than that in adults. Overall, it is estimated that 90% of tu-
berculosis disease in young children occurs within one year of in-
fection (Marais 2014). Despite age being a key predictor of disease
progression, other factors such as nutritional status, immune-com-
promising conditions (e.g. HIV infection), BCG (bacillus Cal-
mette-Guérin) vaccination status, and genetic susceptibility also
contribute to the risk of disease progression. Immediately follow-
ing infection with M tuberculosis in a child, haematogenous spread
(by way of the bloodstream) can occur. The highest risk period for
presentation with tuberculous meningitis and miliary tuberculosis
is one to three months following primary infection. Children be-
tween six months and two years of age are at particularly high risk
of these severe forms of tuberculosis disease. Approximately 50%
of children in this age range progress to tuberculosis disease fol-
lowing infection, and 20% to 40% of those children will present
with disseminated disease (Marais 2004; Marais 2014). Children
under five years of age most commonly present with hilar lymph
node and bronchial forms of intrathoracic tuberculosis disease.
Older children and adolescents more commonly manifest adult-
type disease, including pleural tuberculosis and upper lobe con-
solidations (Marais 2004).
Laboratory confirmation of childhood tuberculosis disease is chal-
lenging for two reasons. The first reason is that child tuberculo-
sis most commonly represents a primary disease process, without
the formation of cavities (Marais 2006a). The number of acid-
fast bacilli in forms of primary tuberculosis such as hilar lymph
node or bronchial tuberculosis is generally substantially lower than
is found in a pulmonary cavity. Consequently, child tuberculosis
is often referred to as being paucibacillary, and it is more diffi-
cult to obtain the organisms needed to confirm disease via con-
ventional smear or culture (Dunn 2016). The second reason for
the difficulty in confirming childhood tuberculosis disease is that
most children younger than six years of age lack the ability to
expectorate sputum and are unable to voluntarily produce good-
quality specimens. Respiratory specimens are therefore often ob-
tained through sputum induction. Children swallow respiratory
secretions, and early-morning gastric aspiration is another well-
established approach to specimen collection. The yield of three
consecutive morning aspirates is similar to the collection of one
induced sputum (Zar 2005). Nasopharyngeal aspiration for res-
piratory specimens is a less invasive and promising mode of spec-
imen collection (Zar 2012). Stool has also been studied as a child
tuberculosis diagnostic specimen; although sensitivity has been
lower than with traditional specimens, this specimen has great ap-
peal because collection is non-invasive and requires no training
(Nicol 2013). Because laboratory diagnostics for tuberculosis per-
form poorly in children, algorithms involving signs, symptoms,
tuberculosis exposure, laboratory tests, and radiographic findings
are commonly used to make a clinical diagnosis of child tuber-
culosis. However, these algorithms have been shown to perform
differently across settings, and their sensitivity and specificity may
be site-specific (David 2017).
Index test(s)
The index tests in this review are Xpert MTB/RIF and Xpert
Ultra (Cepheid Inc, CA, USA). Xpert MTB/RIF and Xpert Ul-
tra are nucleic acid amplification tests (NAATs) and function as
an automated, closed system that performs real-time polymerase
chain reaction (PCR). Specimens are processed using Xpert Sam-
ple Reagent and incubated for 15 minutes, after which the pro-
cessed samples are pipetted into the cartridge. The tests can be run
by operators (such as laboratory technicians and nurses) with min-
imal technical expertise. Within two hours, the tests detect both
live and dead Mycobacterium tuberculosis complex DNA and si-
multaneously recognize mutations in the Mycobacterium tubercu-
losis gene encoding the beta subunit of RNA polymerase (rpoB)
gene, which is the most common site of M tuberculosis mutations
leading to rifampin resistance. Xpert MTB/RIF and Xpert Ultra
require an uninterrupted and stable electrical power supply, tem-
perature control, and yearly calibration of the cartridge modules
(WHO 2014b). TheWHO has published extensive guidance and
practical information on implementing the test (WHO 2014b).
There have been five generations of the cartridge: G1, G2, G3,
G4, and Xpert Ultra. G1 to G4 cartridges initially improved the
detection of tuberculosis and rifampicin resistance. However, in
children, Xpert MTB/RIF detects only 11% of all clinical and
confirmed cases (Detjen 2015). Xpert Ultra was developed in part
to overcome this limitation. There are limited data on the different
sensitivity that Xpert Ultra offers as compared to the G4 cartridge;
however, existing data suggest it may offer improved sensitivity
for tuberculosis detection in hard-to-diagnose populations such
as children, HIV-associated tuberculosis, and extrapulmonary tu-
berculosis (WHO 2017; Dorman 2018). To improve detection
of M tuberculosis, Xpert Ultra incorporates two different multi-
copy amplification targets (IS6110 and IS1081). These revisions
resulted in an approximately 1-log improvement in the lower limit
of detection compared with Xpert MTB/RIF, including improved
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differentiation of certain silent mutations, improved detection of
rifampicin resistance in mixed infections, and avoidance of false-
positive results for detection of rifampicin resistance in paucibacil-
lary specimens (Chakravorty 2017). As mentioned above, Xpert
Ultra also has decreased specificity compared to G4 and may be
more likely to identify M tuberculosis DNA from prior episodes of
tuberculosis disease, particularly in patients classified in the new
‘trace’ category (Dorman 2018). Trace call corresponds to the low-
est bacillary burden for M tuberculosis detection, described below
(WHO 2017). This Cochrane Review will include studies that
used any of the Xpert generations in the diagnosis of tuberculo-
sis (pulmonary tuberculosis, tuberculous meningitis, and lymph
node tuberculosis) in children younger than 15 years.
Clinical pathway
Figure 1 is an example of the clinical pathway and the placement of
the index tests. A careful clinical history of tuberculosis exposure
and symptoms is the first step in the diagnostic pathway for child-
hood tuberculosis. Children with household or other close and
persistent exposure to a person with tuberculosis are at increased
risk of tuberculosis infection and resultant progression to tuber-
culosis disease. All children with recent exposure to tuberculosis
must be evaluated for clinical symptoms and examination findings
consistent with tuberculosis disease. Additional testing depends
on the context, but may include chest radiograph and a test of
tuberculosis infection. Symptoms of tuberculosis disease are gen-
erally persistent for greater than two weeks and are unremitting
(Marais 2005). Themost common symptoms are cough, fever, de-
creased appetite, weight loss or failure to thrive, and fatigue or re-
duced playfulness. Symptoms of extrapulmonary tuberculosis are
typically localized, and diagnostic findings are generally obtained
from the site of disease (Figure 1). However, no symptom-based
diagnostic algorithms have been validated or have been shown to
be reliable in multiple contexts. Symptom-based diagnostic algo-
rithms tend to perform poorly in children under three years of
age and HIV-positive children, two populations at high risk for
disease progression (Marais 2006b).
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Figure 1. Abbreviations: AFB: acid-fast bacilli; CT: computed tomography; LAM: mycobacterial
lipoarabinomannan antigen; MRI: magnetic resonance imaging; NAAT: nucleic acid amplification test; TB:
tuberculosis; TST: tuberculin skin test. The Clinical Pathway. Clinical suspicion of tuberculosis includes
persistent cough, fever, weight loss or failure to thrive, lymphadenitis, irritability, lethargy, headache, vomiting
or neurological symptoms, history of possible or confirmed exposure to M tuberculosis, increased risk for
tuberculosis disease due to immunocompromising conditions.
1Availability of investigations and tests may be different in high- and low-resource settings and may influence
the approach to the diagnosis of child tuberculosis.
2Non-microbiological confirmation of M tuberculosis does not exclude tuberculosis disease in children,
therefore initiation of treatment should be considered empirically if other clinical indications are present.
3Mycobacterial culture results are rarely timely to aid the decision to initiate treatment but can confirm or
refute clinical decision-making if positive.
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Unfortunately, there are no examination features specific to PTB
in children.However, the examination findings in extrapulmonary
tuberculosis can be quite specific when identified. Clinicians
should consider medical comorbidities that increase the risk for
tuberculosis disease andmodify diagnostic algorithms accordingly.
HIV infection not only significantly increases risk of tubercu-
losis in the paediatric population, but also raises the risk of in-
creased disease severity. HIV-positive children often present with
advanced tuberculosis such as disseminated extrapulmonary tu-
berculosis forms and have high levels of immunosuppression, fur-
ther complicating diagnosis and management.
Additional diagnostic imaging studies can assist in the diagnosis
of nearly all forms of PTB and extrapulmonary tuberculosis. Tests
of tuberculosis infection, such as interferon gamma release assays
or tuberculin skin tests, can also aid in establishing the diagnosis
of tuberculosis in a child but are not necessary to make the di-
agnosis. Diagnostic recommendations strongly suggest collecting
appropriate specimens from the suspected sites of involvement in
both PTB and extrapulmonary tuberculosis for microbiological
examination. The preferred sample in PTB is sputum, however in
young children that cannot expectorate, the sample is commonly
obtained via a gastric aspirate or induced sputum. To diagnose
extrapulmonary tuberculosis, the collection of samples targets the
affected site of disease.
The purpose of Xpert is diagnosis of active tuberculosis (PTB and
extrapulmonary tuberculosis) and detection of rifampicin resis-
tance. The results of Xpert can be used as a decision-making tool
in the following ways:
• M tuberculosis detected/rifampicin resistance not detected:
child would start treatment for drug-sensitive tuberculosis;
• M tuberculosis detected/rifampicin resistance detected: child
would need further resistance testing and would start treatment
for drug-resistant tuberculosis according to the country
guidelines;
• M tuberculosis not detected: a negative Xpert result does not
rule out tuberculosis disease, therefore clinicians should still
consider initiation of tuberculosis treatment in children with
history and clinical features suggestive of tuberculosis disease
despite a negative Xpert result. A negative Xpert result may also
represent a true negative.
Possible consequences of a false-positive and a false-negative result
may include the following:
• false positives (FP): children and their families would likely
experience anxiety and morbidity caused by additional testing,
unnecessary treatment, and possible adverse effects; possible
stigma associated with a tuberculosis or drug-resistant
tuberculosis diagnosis and the chance that a false positive may
halt further diagnostic evaluation;
• false negatives (FN): would imply an increased risk of
morbidity and mortality and delayed treatment initiation for
patients.
Alternative test(s)
Alternative approaches to Xpert for diagnosis of tuberculosis are
still used extensively globally. Main tests include the examination
of smears for acid-fast bacilli (tuberculosis bacteria) under a mi-
croscope (lightmicroscopy, using the classical Ziehl-Neelsen stain-
ing technique), fluorescence microscopy, or light-emitting diode
(LED)-based fluorescence microscopy. The sensitivity of smear
microscopy ranges from 0% to 10% in children (Kunkel 2016).
Examination of histology specimens under amicroscope following
a tissue biopsy targets finding acid-fast bacilli and granulomatous
inflammation, frequently with caseous necrosis (necrotizing gran-
ulomas), however these options are seldom pursued to diagnose
child tuberculosis in low-resource settings due to the invasive na-
ture of the procedures and technical expertise required. Lipoarabi-
nomannan (LAM) antigen is a lipopolysaccharide present in my-
cobacterial cell wall that can be detected in the urine of people
with tuberculosis disease (Shah 2016). This urine test has poten-
tial advantages over sputum-based testing due to ease of sample
collection. However, due to poor performance (low sensitivity and
low specificity), the WHO does not recommend its use in HIV-
negative individuals (Nicol 2014). LAM testing is currently rec-
ommended in HIV-positive children presenting with tuberculosis
symptoms and a CD4 count of less than 100 cells/mm3 or with
severe illness (WHO 2015a).
The quest for novel and more efficient technologies for tubercu-
losis diagnosis is a cornerstone of the current efforts to reduce the
burden of disease worldwide. Over the past decade, there has been
unprecedented activity focused on the development of new tools
for extrapulmonary tuberculosis diagnosis, largely supported by
the engagement of global agencies. As a result there is a strong
pipeline of new tools for tuberculosis diagnosis that will comple-
ment the use of existing ones and offer improved options (Boyle
2017).
Rationale
Timely and reliable diagnosis of tuberculosis in children remains
challengingdue todifficulties in collecting sputum samples and the
paucibacillary nature of the disease. As a result, undiagnosed cases
of disease increase morbidity, mortality, and disease transmission
in this key group.
In 2013, informed by a non-Cochrane review (Detjen 2015), the
WHO recommended the use of Xpert MTB/RIF in children as
front-line test for diagnosis. Detjen 2015 found that evaluated
against a reference standard of culture, XpertMTB/RIF had a sen-
sitivity of 62% (95% credible interval 51% to 73%) and a speci-
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ficity of 98% (95% credible interval 97% to 99%). In preparation
for a WHO meeting to review recommendations on the use of
Xpert, wewill perform aCochrane Review to update the literature,
assess the accuracy of both Xpert MTB/RIF and Xpert Ultra, and
address previously noted limitations in the prior review, including
the following:
• low number of included studies;
• referral bias, with a predominance of studies reporting on
hospitalized children;
• heterogeneity in the definition of clinical tuberculosis
among the included studies.
We are aware of one other systematic review on the diagnostic
accuracy of XpertMTB/RIF in children (Wang 2015). This review
found that XpertMTB/RIF had a pooled sensitivity of 65% (95%
confidence interval 61% to 69%) and pooled specificity of 99%
(95% confidence interval 98% to 99%) against a culture reference
standard, concluding thatXpertMTB/RIF is an appropriate initial
diagnostic. This review had similar limitations to those of Detjen
2015 outlined above.
This review will address these limitations by including additional
studies published since 2015 and will include new data on the
performance of Xpert Ultra.
O B J E C T I V E S
Primary objectives
To determine the diagnostic accuracy of Xpert MTB/RIF and
Xpert Ultra for a) PTB in children presumed to have tuberculosis;
b) lymph node tuberculosis in children presumed to have tuber-
culosis; c) tuberculous meningitis in children presumed to have
tuberculosis; and d) rifampicin resistance in children presumed to
have tuberculosis.
For tuberculosis detection, the role of the index tests would be a
replacement for standard practice.
For rifampicin resistance detection, the role of the index tests
would be an initial replacement test for culture-based drug sus-
ceptibility testing.
Secondary objectives
• To compare the accuracy of Xpert MTB/RIF and Xpert
Ultra for each of the four target conditions;
• To investigate potential sources of heterogeneity in accuracy
estimates. For tuberculosis detection, covariates include age,
disease severity, smear-test status, HIV status, clinical setting,
specimen type, high tuberculosis burden, and high tuberculosis/
HIV burden. For rifampicin resistance detection, the covariate of
interest is multidrug-resistant tuberculosis burden.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include cross-sectional studies, cohort studies, and ran-
domized controlled trials from all settings. We will include ran-
domized controlled trials because we may identify studies that
evaluate the use of the test on patient health outcomes, but that
also report sensitivity and specificity. Although the study design is
a randomized trial for the purpose of determining the impact of
the test versus a comparator (e.g. usual practice or another test) on
health outcomes, the study design is a cross-sectional design for
the purpose of determining diagnostic accuracy for the index test
in the Cochrane Review protocol. We must be able to extract or
derive data on the index test being a true positive, false positive,
true negative, or false negative as measured against the reference
standards specified below. Wewill make note of unpublished stud-
ies in the ‘Ongoing studies’ section of the review. We will exclude
case-control studies and case reports.We will use abstracts to iden-
tify published studies and include those that meet the inclusion
criteria.
Participants
We will include studies assessing the index tests for PTB or extra-
pulmonary tuberculosis in HIV-positive and HIV-negative chil-
dren aged 0 to 14 years presumed to have tuberculosis. Studies will
be eligible for inclusion if they describe the use of Xpert (Xpert
MTB/RIF and XpertUltra) on routine respiratory specimens such
as expectorated or induced sputum, gastric lavage, and nasopha-
ryngeal aspirates. We will include bronchoalveolar lavage. We will
also include studies evaluating stool because tuberculosis bacilli are
present in swallowed sputum and recoverable from stool samples
using Xpert.We will also include studies that assessed several types
of specimens.
Index tests
The index tests will be Xpert MTB/RIF and Xpert Ultra.
Index test results are automatically generated, and the user is pro-
vided with a printable test result as follows.
• MTB (M tuberculosis) DETECTED; Rif (rifampicin)
resistance DETECTED;
• MTB DETECTED; Rif resistance NOT DETECTED;
• MTB DETECTED; Rif resistance INDETERMINATE;
• MTB NOT DETECTED;
• INVALID (the presence or absence of MTB cannot be
determined);
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• ERROR (the presence or absence of MTB cannot be
determined);
• NO RESULT (the presence or absence of MTB cannot be
determined).
Xpert Ultra incorporates a semi-quantitative classification for re-
sults: trace, very low, low, moderate, and high. ‘Trace’ corresponds
to the lowest bacterial burden for detection of M tuberculosis
(Chakravorty 2017). Although no rifampicin resistance result will
be available for patients with trace results, a trace-positive result is
sufficient to initiate anti-tuberculosis therapy in children or HIV-
positive patients, according to the WHO report (WHO 2017).
Hence, we will consider a trace result to mean M tuberculosis DE-
TECTED.
Target conditions
The target conditions are active PTB; two forms of extrapul-
monary tuberculosis, lymph node tuberculosis and tuberculous
meningitis; and rifampicin resistance.
Reference standards
For PTB, there are two reference standards: (1) a bacteriological
reference standard, and (2) a clinical reference standard.
A patient with bacteriologically confirmed PTB is one fromwhom
abiological specimen (such as sputumor gastric aspirate) is positive
by smear microscopy or culture. A child with at least one positive
smear or culture will be assigned to the ‘confirmed tuberculosis’
group.
With respect to culture, we will consider studies that use one or
more solid media or commercial liquid cultures or both solid and
liquid culture to confirm tuberculosis.
A patient with clinical PTB is one from whom a biological spec-
imen is negative by both smear microscopy and culture, and
who has been diagnosed with active tuberculosis by a healthcare
provider who, following other clinical criteria, has decided to give
the patient a full course of tuberculosis treatment. This defini-
tion includes patients diagnosed with tuberculosis on the basis of
X-ray abnormalities without bacteriological confirmation (WHO
2014a).
For tuberculous meningitis, there two reference standards: (1) bac-
teriologically confirmed, and (2) clinical diagnosis. A child with
bacteriologically confirmed tuberculous meningitis is defined as
one with a positive culture or positive acid-fast bacillus smear from
a sample of cerebrospinal fluid. Clinical diagnosis may be made
based on compatible signs and symptoms, cerebrospinal fluid anal-
ysis, cerebral imaging, tuberculosis exposure history, and response
to therapy (see Figure 1), leading to initiation of tuberculosis treat-
ment despite not having bacteriological confirmation.
For lymph node tuberculosis, there are two reference standards:
(1) bacteriologically confirmed, and (2) clinical diagnosis. A child
with bacteriologically confirmed lymph node tuberculosis is de-
fined as one with a positive culture or positive acid-fast bacillus
smear from a sample of a node collected from fine needle biopsy
or tissue biopsy or histology consistent with tuberculosis, such as
necrotizing granulomas. Clinical diagnosis may be made based
on compatible signs and symptoms, tuberculosis exposure history,
and response to therapy, leading to initiation of tuberculosis treat-
ment despite not having bacteriological confirmation.
A child will be assigned to the ‘not tuberculosis’ group if culture
and smear (if obtained) are both negative and during the evalua-
tion for tuberculosis an alternative diagnosis was established, their
symptoms resolved without tuberculosis treatment, or they did
not progress after at least one month.Wewill not limit the diagno-
sis of clinical tuberculosis to existing consensus definitions, which
would likely be too restrictive (Graham 2012; Graham 2015).
The primary unit of analysis will be the patient, meaning one
Xpert test and one reference standard result for a patient.However,
we anticipate that some studies may include multiple specimens
for a patient. We will perform analyses separately for each unit of
analysis and discuss the limitation of using a unit of analysis other
than the patient.
The reference standard may be applied to the same child singly or
multiple times with a rule, such as at least one positive result, used
to determine index test positivity. Ultimately a child will have only
one reference standard result against which the result of the index
test is cross classified. We will analyse these two ways of applying
the reference standard separately (see Statistical analysis and data
synthesis) and reflect these differences in theQuality Assessment of
Diagnostic Accuracy Studies 2 (QUADAS-2), Reference Standard
domain.
The reference standard for rifampicin resistance will be phenotypic
drug susceptibility testing.
Search methods for identification of studies
We will attempt to identify all relevant studies regardless of lan-
guage or publication status (published, unpublished, in press, and
in progress).
Electronic searches
We will search the following databases using the search terms and
strategy described in Appendix 1: Cochrane Infectious Diseases
Group Specialized Register; Cochrane Central Register of Con-
trolled Trials (CENTRAL), published in the Cochrane Library;
MEDLINE ( Ovid); Embase ( Ovid); CINAHL ( EBSCOHost) (
Cumulative Index to Nursing and Allied Health Literature); Sci-
ence Citation Index-Expanded (Web of Science); and Scopus.We
will search the World Health Organization International Clinical
Trials Registry Platform ( WHO ICTRP) ( www.who.int/ictrp/
en/) and USNational Institutes of HealthOngoing Trials Register
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ClinicalTrials.gov ( clinicaltrials.gov/) for trials in progress using
’tuberculosis’ and ’symptom screening’ as search terms.
Searching other resources
We will contact researchers and experts in the field to identify any
additional eligible studies. We will also check the references of
relevant reviews and studies to identify additional studies.
Data collection and analysis
Selection of studies
Two review authors will independently screen all titles and ab-
stracts in order to identify potentially eligible studies. We will then
obtain the full-text articles of potentially eligible studies, and two
review authors will independently assess whether they should be
included based on predefined inclusion and exclusion criteria. Any
disagreements will be resolved by discussion or by consulting a
third review author if necessary. We will contact study authors for
clarification of methods and other information as needed. We will
record and summarize reasons for exclusion of excluded studies in
a ‘Characteristics of excluded studies’ table. We will illustrate the
study selection process in a PRISMA diagram.
Data extraction and management
We will design a data extraction form and pilot it on at least two
included studies (Appendix 2), and will then finalize the form
based on the pilot test. As above, two review authors will inde-
pendently extract data using this data extraction form, and will
discuss inconsistencies to achieve consensus. They will consult a
third review author to resolve discrepancies as needed. We will
enter abstracted data into an Excel database (Excel 2013) on pass-
word-protected computers. We will secure the dataset in a cloud
storage workspace (Dropbox), and we will store extracted data for
future review updates. A representative list of data extraction fields
is listed below.
Study details
• Number of participants after screening for exclusion and
inclusion criteria;
• total number of children included in the analysis;
• total number of specimens included with collection
methods;
• unit of sample collection: one specimen, multiple
specimens, unknown, or unclear;
• did the study include participants with a prior history of
tuberculosis;
• if so, % (numerator/denominator) of patients with prior
tuberculosis;
• target condition(s)? pulmonary tuberculosis, lymph node
tuberculosis, tuberculous meningitis, rifampicin resistance;
• if so, % (numerator/denominator) of patients with prior
tuberculosis;
• target condition(s)? pulmonary tuberculosis, lymph node
tuberculosis, tuberculous meningitis, rifampicin resistance;
• target condition(s)? pulmonary tuberculosis, lymph node
tuberculosis, tuberculous meningitis, rifampicin resistance.
Patient characteristics and setting
• Description of study population;
• age: median, mean, range and disaggregation into categories
(0 to 4, 5 to 14);
• gender;
• HIV status of participants;
• percentage and number of HIV-positive or HIV-negative
participants, if both were included in the study;
• type of respiratory specimen included: expectorated,
induced, nasopharyngeal aspirate, gastric lavage, stool;
• type of non-respiratory specimen included: fine needle
aspirate, lymph node biopsy, cerebrospinal fluid, multiple types,
other, unknown;
• information obtained from the same specimen;
• number of cultures used to exclude tuberculosis;
• information on smear microscopy: was it used, type,
quantification (trace to 4+);
• data on culture performance: number of contaminated
cultures with respect to total cultures performed;
• time from specimen collection to diagnosis;
• time from diagnosis to treatment initiation;
• clinical setting: outpatient or inpatient or both;
• description of radiographic findings;
• information on tuberculosis burden in the country.
We will classify ‘country’ as being high burden or not high burden
for tuberculosis, tuberculosis/HIV, or multidrug-resistant tuber-
culosis according to theWHOpost-2015 era classification (WHO
2018a). A country may be classified as high burden for one, two,
or all three of the high-burden categories.
Index test
• Xpert version: MTB/RIF or Ultra;
• Xpert platform;
• pretreatment processing procedure for Xpert MTB/RIF or
Xpert Ultra;
• specimen treatment: fresh, frozen, mixed;
• number of true positives, false positives, false negatives, and
true negatives (see example table in Appendix 3);
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• uninterpretable results for tuberculosis detection (invalid,
error, or no result);
• indeterminate results for rifampicin resistance detection.
Reference standard
• Reference standard for PTB: details of solid or liquid
culture or clinical criteria;
• reference standard for M tuberculosis: details of tissue or
histopathology or culture of tissue or fluid, and clinical criteria;
• reference standard for rifampicin resistance: details of
phenotypic drug susceptibility testing.
Assessment of methodological quality
Wewill assess themethodological quality of included studies using
the QUADAS-2 instrument, which we will adapt for this review
(Whiting 2011). The QUADAS-2 tool consists of four domains:
(1) patient selection; (2) index test(s); (3) reference standard(s);
and (4) flow and timing. We will assess all domains for risk of bias,
and the first three domains for concerns regarding applicability.
We will first develop guidance on how to appraise each question
and interpret this information. One review author will then pilot
the tool with two of the included studies. We will finalize the tool
based on experience gained from the pilot. Two review authors will
independently complete QUADAS-2. Any disagreements will be
resolved through discussion or by arbitration with a third review
author if necessary. We will present the results of the quality as-
sessment in the text, table, and graphs. The preliminary tool with
signalling questions tailored to this review is in Appendix 4.
Statistical analysis and data synthesis
When possible, for each target condition, we will consider one
result per index test per child; this ideally corresponds to the first
specimen provided. A positive index test is detection of M tuber-
culosis by Xpert.
For tuberculosis detection and rifampicin resistance detection, we
will group all analyses by the specific index test, Xpert MTB/RIF
or Xpert Ultra. For both PTB and extrapulmonary tuberculosis
detection, we will stratify analyses by type of reference standard
used, that is bacteriological or clinical. We will also analyse studies
that report a single result for the reference standard separately from
those that use multiple results for this same reference standard
because we suspect that the latter is likely to correctly identify
more tuberculosis patients.
For detection of rifampicin resistance, we will include children
who:
• were culture-positive;
• had a valid phenotypic drug susceptibility test (DST) result;
• were Xpert tuberculosis-positive; and
• had a valid Xpert rifampicin result.
Sensitivity = Xpert rifampicin resistant/phenotypic DST ri-
fampicin resistant
Specificity = Xpert rifampicin susceptible/phenotypic DST ri-
fampicin susceptible
We will perform descriptive analyses of the included studies and
present their key characteristics in ‘Characteristics of included
studies’ tables. We will present individual study estimates of sen-
sitivity and specificity graphically on forest plots and in receiver
operating characteristics (ROC) space using Review Manager 5
(RevMan 2014).
We expect that some studies will consider index test results from
more than one specimen. We will use the following two analytic
approaches to consider multiple specimen results:
• consider only the first specimen result;
• consider all results and define positive as ‘at least one
positive result’.
If the sample size supports meaningful analysis, secondary analysis
will look at performance of the index test stratified by number of
samples tested.
When there are sufficient data, we will perform meta-analyses to
estimate an average summary value of sensitivities and specificities
using a bivariate model (Chu 2006; Reitsma 2015). We will use
the bivariate model because the index tests, Xpert MTB/RIF and
Xpert Ultra, each apply a common positivity criterion (Macaskill
2010). If we are unable to fit the bivariatemodels due to sparse data
or few studies, we will simplify the models to univariate random-
effects logistic regression models to pool sensitivity and specificity
separately (Takwoingi 2015).Wewill performmeta-analyses using
the meqrlogit command in Stata version 15 (Stata 15).
If there are sufficient data, we will perform comparative meta-
analyses by first including all studies with relevant data, employ-
ing indirect comparisons to make use of all available data. When
comparative studies that made direct comparisons between Xpert
MTB/RIF and Xpert Ultra within the same participants are avail-
able, wewill perform additional analyses by restricting the analyses
to only these comparative studies. We will perform comparative
meta-analyses using meta-regression by including test type as a
covariate in a bivariate model. We will assess model fit using like-
lihood ratio tests to compare models with and without the covari-
ate terms. We will calculate absolute differences in sensitivity and
specificity using the bivariate model parameters. We will obtain
95% confidence intervals and P values for the absolute differences
using the delta method and Wald tests, respectively.
Approach to uninterpretable index test results
Xpert MTB/RIF and Xpert Ultra report an uninterpretable test
result for unexpected results with any of the internal control mea-
sures of the assay. The uninterpretable rate for detection of tu-
berculosis is the number of tests classified as “invalid”, “error”, or
“no result” divided by the total number of Xpert tests performed.
The indeterminate rate for detection of rifampicin resistance is the
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number of tests classified as “MTB DETECTED; Rif resistance
INDETERMINATE” divided by the total number of Xpert-pos-
itive results. If we find a low proportion of uninterpretable results
for tuberculosis detection or a low proportion of indeterminate
results for rifampicin resistance detection, we will exclude these
results from the analysis and report the pooled proportion of un-
interpretable Xpert MTB/RIF results and Xpert Ultra results for
tuberculosis detection and indeterminate Xpert MTB/RIF results
and Xpert Ultra results for rifampicin resistance detection. Oth-
erwise, we plan to group these results with either the positive or
negative results and perform additional analyses.
Investigations of heterogeneity
We will visually inspect forest and summary receiver operating
characteristic (ROC) plots for heterogeneity. If the data allow,
we will evaluate sources of heterogeneity using bivariate meta-
regression with each source of heterogeneity as a single covariate
in a bivariate model. We plan to assess the following as categorical
covariates.
Tuberculosis detection
• Smear status (positive or negative);
• HIV status (percentage positive in the study);
• clinical setting (inpatient or outpatient);
• specimen type (collection method);
• age (age group);
• high tuberculosis burden, yes or no;
• high tuberculosis/HIV burden, yes or no.
Rifampicin resistance detection
• High multidrug-resistant tuberculosis burden, yes or no.
Sensitivity analyses
If there are sufficient data, we will perform sensitivity analyses to
explore the effect of risk of bias and study characteristics on the
accuracy of Xpert MTB/RIF and Xpert Ultra. Specifically, we will
limit inclusion in the meta-analyses to the following:
• studies that used consecutive or random selection of
participants;
• studies where the reference standard results were interpreted
without knowledge of the index test results;
• studies that included only untreated patients;
• studies that only enrolled children aged 0 to 14 years old.
Assessment of reporting bias
We will not formally assess reporting bias using funnel plots or
regression tests as these have not been reported as helpful for di-
agnostic test accuracy studies (Macaskill 2010).
Assessment of certainty of the evidence
We will assess the certainty of evidence using the GRADE ap-
proach for diagnostic studies (Balshem 2011; Schünemann 2008;
Schünemann 2016). As recommended, we will rate the certainty
of evidence as either high (not downgraded), moderate (down-
graded by one level), low (downgraded by two levels), or very low
(downgraded by more than two levels) based on five domains: risk
of bias, indirectness, inconsistency, imprecision, and publication
bias. For each outcome, the certainty of evidence will start as high
when there are high-quality observational studies (cross-sectional
or cohort studies) that enrolled participants with diagnostic un-
certainty. If we find a reason for downgrading, we will use our
judgement to classify the reason as either serious (downgraded by
one level) or very serious (downgraded by two levels). Three review
authors (AWK, LGF, and KRS) will discuss judgments and apply
GRADE in the following way.
Assessment of risk of bias
We will use QUADAS-2 to assess risk of bias.
Indirectness
We will us QUADAS-2 for concerns of applicability and look
for important differences between the populations studied (for
example, in the spectrum of disease), the setting, index test, and
outcomes and ask if differences are sufficient to lower certainty in
results?
Inconsistency
GRADE recommends downgrading for unexplained inconsis-
tency in sensitivity and specificity estimates. We will carry out pre-
specified analyses to investigate potential sources of heterogeneity
and will downgrade when we think we can explain inconsistency
in the accuracy estimates. Imprecision: we consider a precise esti-
mate to be one that would allow a clinically meaningful decision.
We will consider the width of the CI, and ask, “Would we make a
different decision if the lower or upper boundary of the CI repre-
sented the truth?” In addition, we will work out projected ranges
for TP, FN, TN, and FP for a given prevalence of tuberculosis
and make judgements on imprecision from these calculations. We
will also consider whether the number of participants included in
the analysis was less than the number generated by a conventional
sample size calculation for a single adequately powered study (op-
timal information size).
Publication bias
Wewill rate publication bias as undetected (not serious) for several
reasons including the comprehensiveness of the literature search
and extensive outreach to tuberculosis researchers to identify stud-
ies.
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A P P E N D I C E S
Appendix 1. Search strategy
1 Mycobacterium tuberculosis/
2 Tuberculosis/ or “Tuberculosis, Multidrug-Resistant”/ or Extensively Drug-Resistant Tuberculosis/
3 (Tuberculosis or MDR-tuberculosis or XDR-tuberculosis or tuberculous).ti. or (Tuberculosis or MDR-tuberculosis or XDR-tuber-
culosis or tuberculous).ab.
4 1 or 2 or 3
5 Xpert*.ti. or Xpert*.ab.
6 (GeneXpert or cepheid).ti. or (GeneXpert or cepheid).ab.
7 (Xpert* and Ultra).mp.
8 near* patient or near-patient).ti. or (near* patient or near-patient).ab.
9 (pediatric( or paediatric).mp.
10 (child or children or childhood or infant* or newborn or neonate* or toddler*).mp
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11 5 or 6 or 7 or 8
12 9 or 10
13 4 and 11 and 12
This is the preliminary search strategy for MEDLINE (Ovid), which will be adapted for other electronic databases. We will report all
search strategies in full in the final review version.
Appendix 2. Data extraction form
Diagnostic accuracy of Xpert in the diagnosis of child tuberculosis: data extraction form
I. ID
Study ID First Name/Publication Year
First Author Name
Corresponding author Name
Corresponding author email Email
Was author contacted? 1 - Yes
2 - No
If yes, dates(s)
If yes, author response?




Year (of publication) YYYY or 9 - Not reported
Year study start date YYYY or 9 - Not reported




Country where study was conducted
Country World Bank classification 1 - Low income
2 - Middle income
3 - High income
4 - Low and High income
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(Continued)
5 - Other combination, describe
Country tuberculosis burden (WHO 2015b) 1 - WHO tuberculosis high burden
2 - WHO tuberculosis/HIV high burden
3 - WHO MDR tuberculosis high burden
4 - WHO tuberculosis + MDR tuberculosis high burden
5 - WHO tuberculosis + HIV/tuberculosis high burden
6 - WHO tuberculosis + HIV/tuberculosis + MDR tuberculosis
high burden
7 - Not a WHO high-burden country
8 - Both non-high-burden and high-burden countries included
9 - Other
Study design 1 - Randomized controlled trial
2 - Cross-sectional
3 - Cohort
4 - Other, specify
9 - Could not tell
If other, describe:




9 - Unknown/Not reported
Direction of study data collection 1 - Prospective
2 - Retrospective
9 - Unknown/Not reported
Inclusion criteria 1 - Broad
2 - Rigorous
9 - Unknown/Not reported
Inclusion criteria for presumptive tuberculosis 1 - tuberculosis contact
2 - Cough
3 - Loss of weight
4 - Suggestive chest x-ray




8 - Other, describe
9 - Unknown/Not reported
Describe inclusion criteria as in study
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(Continued)
Number included after recruitment by inclusion and exclusion
criteria
Enter number or 9 - Unknown/Not reported
Total number of children included in systematic review analysis Enter number or 9 - Unknown/Not reported
Total number of specimens included in analysis with collection
method
Enter number or 9 - Unknown/Not reported
Unit of analysis (Xpert) 1 - One specimen per patient
2 - Multiple specimens per patient
3 - Unknown number of specimens per patient
9 - Unknown/Not reported
Describe as written in study, if unclear:
Did the study include patients with previous tuberculosis history? 1 - Yes
0 - No
9 - Unknown/Not reported
If so, what is the percentage? Enter % and specify numerator/denominator
Target condition? Pulmonary tuberculosis? 1 - Yes
0 - No
Target condition? Rifampicin resistance? 1 - Yes
0 - No
Target condition? Lymph node tuberculosis? 1 - Yes
0 - No
Target condition? Tuberculous meningitis? 1 - Yes
0 - No
Comments about study design
III. Patient characteristics and setting
Description of study population (age, HIV info, etc.) 1 - All enrolled
2 - All analysed
9 - Unknown/Not reported
Age: median, mean, range by months Enter number or 9 - Unknown/Not reported
Gender ##/total and % female
HIV status of participants 0 - HIV−
1 - HIV+
2 - Both HIV+/−
9 - Unknown/Not reported
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(Continued)
If HIV-positive participants included, what is the percentage? % and specify numerator/denominator
Type of respiratory specimen included 1 - All expectorated
2 - All induced
3 - All Bronchoalveolar lavage
4 - All gastric lavage
5 - Nasopharyngeal aspitate
6 - Stool
7 - Multiple types
8 - Other
9 - Unknown/Not reported
If 7 or 8, describe types and record numbers:
Type of non-respiratory specimen 1 - Fine needle aspirate
2 - Lymph node biopsy
3 - Cerebrospinal fluid
4 - Multiple types
5 - Other
9 - Unknown/Not reported
If 4 or 5, describe types and record numbers:
Were Xpert sample and culture obtained from same specimen? 1 - Yes
0 - No
9 - Unknown/Not reported
Number of cultures used to exclude tuberculosis Describe
Information on smear microscopy: was it used 1 - Yes
0 - No
9 - Unknown/Not reported
Type of microscopy used 1 - Ziehl-Neelsen
2 - Fluoresence microscopy
3 - Light Emitting Diode-based fluorescence microscopy
4 - Multiple, describe
9 - Unknown/Not reported
Smear type 1 - Direct
2 - Concentrated (processed)
3 - Both direct and concentrated
9 - Unk/NR
Data on culture performance provided? # of contaminated culture/Total # cultures performed
or 9 - Unknown/Not reported
Were patient important outcomes evaluated?
(Time to diagnosis, time to treatment, others)
1 - Yes
2 - No
9 - Unknown/Not reported
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(Continued)
Time to diagnosis? Xpert:
Culture:
9 - Unknown/Not reported
Specify whether time from sample collection to diagnosis in lab
or just turnaround time in lab
Time to treatment initiation Xpert:
Culture:
9 - Unknown/Not reported
Clinical setting, describe as written in the paper 1 - Outpatient
2 - Inpatient
3 - Both out- and inpatient
4 - Other, specify
5 - Laboratory based
9 - Unknown/Not reported
Describe as in paper:
Laboratory services level 1 - Central (reference)
2 - Intermediate (regional)
3 - Peripheral (microscopy centre, provincial hospital)
4 - Research laboratory
5 - Other, specify
Where were Xpert tests performed?
(Tests generally available at different laboratory levels, though tests
may overlap)
Peripheral: Acid-fast bacilli (Ziehl-Neelsen, Auramine-rho-
damine, Auramine-O staining) and Xpert MTB/RIF
Intermediate: Peripheral laboratory tests and culture on solid me-
dia and line probe assay (LPA) from smear positive sputum
Central: Intermediate laboratory tests and culture on liquid media
and DST (1st- and 2nd-line anti-tuberculosis drugs) on solid or
in liquid media and LPA on positive cultures and rapid speciation
tests
1 - Central (reference)
2 - Intermediate (regional)
3 - Peripheral (microscopy centre, provincial hospital)
4 - Other, specify
Was Xpert run outside of a laboratory? 1 - Yes
0 - No
Current treatment: Were patients on treatment (defined as tuber-
culosis drugs for greater than 7 days) for the current tuberculosis
episode? (note: may impact culture results)
1 - Yes
2 - No
9 - Unknown/Not reported
If so, what is the percentage? % Specify numerator/denominator
IV. Index test
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(Continued)
Xpert version(s) evaluated 1 - Xpert only
2 - Ultra only
3 - Any combination Xpert and Ultra
Xpert platform: Was Omni used? Unless Omni explicitly de-
scribed, assume standard platform
1 - Yes, only Omni used for Xpert tests
2 - Yes, both Omni and standard platform used for Xpert tests
3 - No
Pretreatment processing procedure for GeneXpert 1 - None
2 - NALC-NaOH
3 - NaOH (Petroff )
4 - Other
9 - Unknown/Not reported




9 - Unknown/Not reported
Were uninterpretable (invalid error or no result) results reported
for Xpert for tuberculosis detection?
1 - Yes
9 - Unknown/Not reported
If yes, describe numbers




If yes, describe numbers
V. Reference standard
For tuberculosis detection, what reference standard(s) was used?
Respiratory Samples?
1 - Solid culture (specify 1a)
2 - Liquid culture (specify 2a)
3 - Both solid & liquid culture (specify 1a & 2a)
9 - Unknown/Not reported





2a - Liquid culture
MGIT 960
Other (specify):
For tuberculosis detection, what reference standard(s) was used?
Lymph node?
1 - Solid culture (specify 1a)
2 - Liquid culture (specify 2a)
3 - Both solid & liquid culture (specify 1a & 2a)
9 - Unknown/Not reported
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(Continued)





2a - Liquid culture
MGIT 960
Other (specify):
For tuberculosis detection, what reference standard(s) was used?
Cerebrospinal fluid?
1 - Solid culture (specify 1a)
2 - Liquid culture (specify 2a)
3 - Both solid & liquid culture (specify 1a & 2a)
9 - Unknown/Not reported





2a - Liquid culture
MGIT 960
Other (specify):
Reference standard pulmonary tuberculosis: clinical 1 - Yes
0 - No
Multiple answers, list
If clinical describe as in paper
For rifampicin resistance detection, what reference standard(s) was
used?
Respiratory samples?
1 - Solid culture (specify 1a)
2 - Liquid culture (specify 2a)
3 - Both solid & liquid culture (specify 1a & 2a)
4 - M tuberculosis DRplus
9 - Unknown/NR





Specify method, e.g. proportion
2a - Liquid culture
MGIT 960
Other (specify):
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(Continued)
For rifampicin resistance detection, what reference standard(s) was
used?
Lymph node?
1 - Solid culture (specify 1a)
2 - Liquid culture (specify 2a)
3 - Both solid & liquid culture (specify 1a & 2a)
4 - M tuberculosis DRplus
9 - Unknown/Not reported





Specify method, e.g. proportion
2a - Liquid culture
MGIT 960
Other (specify):
For rifampicin resistance detection, what reference standard(s) was
used?
Cerebrospinal fluid?
1 - Solid culture (specify 1a)
2 - Liquid culture (specify 2a)
3 - Both solid & liquid culture (specify 1a & 2a)
4 - M tuberculosis DRplus
9 - Unknown/Not reported





Specify method, e.g. proportion
2a - Liquid culture
MGIT 960
Other (specify):
If information is available
Is information on quality assurance of DST available in the study? 1 - Yes
2 - No
9 - Unknown/Not reported
If yes, describe potential sources of bias
Abbreviations: DST: Drug susceptibility testing; HIV: human immunodeficiency virus; IGRA: Interferon-gamma release sssays; LJ:
Lowenstein Jensen; MDR-TB: Multidrug-resistant tuberculosis; MGIT: Mycobacterial growth indicator tube; TST: Tuberculin skin
test
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Appendix 4. QUADAS-2 review-specific guidance
Domain 1: Patient selection
Risk of bias: Could the selection of patients have introduced bias?
Signalling question 1: Was a consecutive or random sample of patients enrolled?.We will answer ‘yes’ if the study enrolled a consecutive
or random sample of eligible patients; ‘no’ if the study selected patients by convenience; and ‘unclear’ if the study did not report the
manner of patient selection or we cannot tell.
Signalling question 2: Did the study avoid inappropriate exclusions?
a. Pulmonary tuberculosis - We will score yes for all studies because we do not think there are any inappropriate exclusions for children
presumed to have PTB
b. Extrapulmonary tuberculosis (lymph node tuberculosis and tuberculous meningitis) - We will score ‘no’ if the study excluded
specimens based on physical appearance (such as purulence) or a biochemical analysis (e.g. adenosine deaminase (ADA) or cell analysis).
We will score ‘unclear’ if we cannot tell.
Applicability: Are there concerns that the included patients and setting do not match the review question?
We are interested in how Xpert performs in patients who were evaluated as they would be in routine practice. Paediatric studies
conducted in tertiary centres tend to include a higher number of children with advanced disease, therefore we will answer ‘low concern’
if patients were evaluated in local hospitals or primary care centres; ‘high concern’ if patients were evaluated exclusively as inpatients
in tertiary care centres; and ‘unclear concern’ if the clinical setting was not reported or there was insufficient information to make
a decision. We will also answer ‘unclear concern’ if Xpert testing was done at a reference laboratory and the clinical setting was not
reported, because it is difficult to tell if a given reference laboratory provides services mainly to very sick patients (inpatients in tertiary
care) or to patients with a broad spectrum of disease, including very sick patients and those with less severe disease (primary, secondary,
and tertiary care).
Domain 2: Index test
Risk of bias: Could the conduct or interpretation of the index test have introduced bias?
Signalling question 1: Were the index test results interpreted without knowledge of the results of the reference standard?. We will
answer this question ‘yes’ for all studies because Xpert MTB/RIF and Xpert Ultra test results are automatically generated, and the user
is provided with printable test results, thus there is no room for subjective interpretation of test results.
Signalling question 2: If a threshold was used, was it prespecified? The threshold is prespecified in all versions of Xpert MTB/RIF and
Xpert Ultra. We will answer this question ‘yes’ for all studies.
Applicability: Are there concerns that the index test, its conduct, or its interpretation differ from the review question? Variations in test
technology, execution, or interpretation may affect estimates of the diagnostic accuracy of a test. GeneXpert, the test device platform,
simplifies molecular testing by fully integrating and automating the three processes (sample preparation, amplification, and detection)
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required for real-time polymerase chain reaction (PCR)-based molecular testing. All steps in the XpertMTB/RIF and Xpert Ultra assays
are completely automated and self contained following sample loading. Minimal training is required by operators such as laboratory
technicians and nurses to run the index test.
For pulmonary tuberculosis, we will answer ‘low concern’ if the index test was performed as recommended by the manufacturer. For
sputum specimens, we will answer ‘unclear concern’ if the ratio of the Xpert sample reagent: specimen volume was not 2:1 for a raw
specimen or 3:1 for a centrifuged sediment as recommended by the manufacturer or if we cannot tell (WHO 2014a). Central-level
laboratories use more highly trained staff than peripheral- and intermediate-level laboratories or health facilities. However, we do not
consider this to be a concern about applicability due to the minimal training required to run the index tests.
With respect to extrapulmonary specimens, the WHO has provided detailed information about the processing steps in ‘Xpert MTB/
RIF implementation manual. Technical and operational “how-to” practical considerations. Annex 2. Standard Operating Procedure
(SOP) for processing extrapulmonary specimens (CSF, lymph nodes and other tissues) for “XpertMTB/RIF assay”’ (WHO 2014b). For
extrapulmonary specimens, we will answer ‘low concern’ if the test was performed according to WHO standard operating procedures.
We will score ‘high concern’ if the test was performed in a way that deviated from these recommendations. We will score ‘unclear
concern’ if we cannot tell.
Domain 3: Reference standard
We have multiple target conditions, each of which each has a different reference standard(s), therefore we have explained how we will
assess each signalling question for each reference standard.
Risk of bias: Could the reference standard, its conduct, or its interpretation have introduced bias?
Signalling question 1.a: Is the bacteriological reference standard likely to correctly classify the target condition?
For pulmonary and extrapulmonary tuberculosis, we anticipate that the vast majority of studies will perform culture. Culture is
considered the best reference standard for tuberculosis diagnosis. However, particularly in children with paucibacillary disease, it is not
100% accurate. Sensitivity ranges roughly between 20% and 50%, depending on the severity of disease, specimen collection, age of
the child, and other factors. The performance of more than one culture increases the diagnostic yield. We will answer ‘yes’ for studies
using multiple specimens and ‘unclear’ for studies using only one specimen.
Signalling question 1.b: Is the clinical reference standard likely to correctly classify the target condition? A clinical definition of
tuberculosis in bacteriologically negative children aims to identify those that were not detected by culture (or histology in the case of
lymph node tuberculosis) for the above-mentioned reasons. The accuracy of this reference standard is also not 100%, and its definition
is heterogeneous across studies. Irrespective of how clinical tuberculosis was defined in the publications, we will assign children to a
group called ‘clinical tuberculosis’ if they were presumed to have tuberculosis and were started on anti-tuberculosis treatment. We will
answer ‘unclear’ for all studies.
For rifampicin resistance, we will answer ‘yes’ if a study used phenotypic culture-based drug susceptibility testing as a reference standard.
As this is an inclusion criterion for the review, we will only include studies for this target condition that satisfy this reference standard.
Signalling question 2: (tuberculosis) Were the reference standard results interpreted without knowledge of the results of the index test?
For pulmonary tuberculosis we will answer ‘yes’ if the reference test provided an automated result (e.g. MGIT 960); blinding was
explicitly stated; or it was clear that the reference standard was performed at a separate laboratory or performed by different people. We
will answer ‘no’ if the study stated that the reference standard result was interpreted with knowledge of the Xpert test result. We will
answer ‘unclear’ if we cannot tell.
For extrapulmonary tuberculosis, we will answer ‘yes’ if the reference test provided an automated result (e.g. MGIT 960); blinding was
explicitly stated; or it was clear that the reference standard was performed at a separate laboratory or performed by different people. We
will answer ‘no’ if the study stated that the reference standard result was interpreted with knowledge of the Xpert test result. We will
answer ‘unclear’ if we cannot tell.
For rifampicin resistance, we will answer ‘yes’ if the reference test provided an automated result (e.g. MGIT 960 SIRE); blinding was
explicitly stated; or it was clear that the reference standard was performed at a separate laboratory or performed by different people. We
will answer ‘no’ if the study stated that the reference standard result was interpreted with knowledge of the Xpert test result. We will
answer ‘unclear’ if we cannot tell.
Applicability: Are there concerns that the target condition as defined by the reference standard does not match the question?
For both pulmonary tuberculosis and extrapulmonary tuberculosis, we will answer ‘high concern’ if the included studies did not
differentiate Mycobacterium tuberculosis complex isolated in culture from other mycobacteria using any speciation technique; ‘low
concern’ if speciation was performed using any technique; and ‘unclear concern’ if we cannot tell.
For rifampicin resistance, we will judge applicability to be of ‘low concern’ for all studies because the method used (phenotypic culture-
based drug susceptibility testing) is appropriate.
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Domain 4: Flow and timing
Risk of bias: Could the patient flow have introduced bias?
Signalling question 1: Was there an appropriate interval between the index test and reference standard? We expect to find for most
included studies that specimens for Xpert and culture were obtained at the same time, when patients were evaluated for presumed
tuberculosis. Even if there were a delay of several days between index test and reference standards, tuberculosis is a chronic disease, and
we consider misclassification of disease status to be unlikely, as long as treatment was not initiated in the interim. We will answer ‘yes’
if the index test and reference standard were performed at the same time or if the time interval was less than or equal to seven days; ‘no’
if the time interval was greater than seven days; and ‘unclear’ if we cannot tell.
Signalling question 2: Did all patients receive the same reference standard? We will answer ‘yes’ if all patients received the same reference
standard; ‘no’ if all patients did not receive the same reference standard; and ‘unclear’ if we cannot tell.
Signalling question 3: Were all patients included in the analysis? We will determine the answer to this question by comparing the
number of patients enrolled with the number of patients included in the 2 x 2 tables. We will answer ‘yes’ if the numbers matched and
‘no’ if there were patients enrolled in the study that were not included in the analysis. We will answer ‘unclear’ if we cannot tell.
Judgements for risk of bias assessments for a given domain:
• If we answer all signalling questions for a domain ‘yes’, then we will judge risk of bias as ‘low’.
• If we answer all or most signalling questions for a domain ‘no’, then we will judge risk of bias as ‘high’.
• If we answer only one signalling question for a domain ‘no’, we will further discuss the risk of bias judgement.
• If we answer all or most signalling questions for a domain ‘unclear’, then we will judge risk of bias as ‘unclear’.
• If we answer only one signalling question for a domain ‘unclear’, we will further discuss the risk of bias judgement for the domain.
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